Skip to Content

Gauri Rajani Varadhachary, MBBS, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1991 L.T.M. Medical College, University of Mumbai, Mumbai, Maharashtra, India, MBBS, Bachelor of Medicine and Bachelor of Surgery

Postgraduate Training

7/1996-6/1997 Clinical Rotations, Melanoma, Sarcoma, Lymphoma, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1994-6/1997 Clinical Fellowship, Hematology and Oncology, Baylor College of Medicine, Houston, TX
7/1991-6/1994 Clinical Residency, Internal Medicine, Greater Baltimore Medical Center (GBMC), Baltimore, MD

Board Certifications

7/2007 American Board of Internal Medicine (Medical Oncology)
5/2004 American Board of Internal Medicine (Internal Medicine)
1998 American Board of Internal Medicine (Hematology)
1/1991 ECFMG

Experience/Service

Academic Appointments

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2006-8/2012
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 6/2003-6/2006
Assistant Professor, Dept. of Medicine, Section of Hematology and Oncology, Baylor College of Medicine, Houston, TX, 12/1999-6/2003

Administrative Appointments/Responsibilities

Clinical Medical Director, Gastrointestinal Center, Multidisciplinary Care Center, Division of Ofc/EVP, Physician-in-Chief, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2013-present
Associate Director, Gastrointestinal Center, Multidisciplinary Care Center, Division of Ofc/EVP, Physician-in-Chief, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2008-5/2013

Institutional Committee Activities

Chair, Integration of Clinical Research in Patient Care Working Group, 9/2012-present
Member, Search Committee, Division Head, Radiation Oncology, 2011
Quality Officer, Ongoing Professional Practice Evaluation/Focused Professional Practice Evaluation (OPPE/FPPE), 2010-present
Leader - Policies and Procedures Subcommittee, 24-Hour Nocturnal Program Task Force, 2010-present
Member - Medical Practice Subcommittee, 24-Hour Nocturnal Program Task Force, 2010-present
Member - Steering Committee, 24-Hour Nocturnal Program Task Force, 2010-present

Honors and Awards

2010 Division of Cancer Medicine's Fifth Annual Faculty Recognition Award for Excellence in Patient Care, Melvin L. Samuels Award for Excellence in Patient Care
2007-2010 Nominated, Division of Cancer Medicine's Annual Faculty Recognition Award, Melvin L. Samuels Award for Excellence in Patient Care

Professional Memberships

American Society of Clinical Oncology
Member/Non Colorectal Cancer, Scientific Committee, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Tran Cao HS, Balachandran A, Wang H, Nogueras-González GM, Bailey CE, Lee JE, Pisters PW, Evans DB, Varadhachary GR, Crane CH, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Radiographic Tumor-Vein Interface as a Predictor of Intraoperative, Pathologic, and Oncologic Outcomes in Resectable and Borderline Resectable Pancreatic Cancer. J Gastrointest Surg 18(2):269-78, 2/2014. e-Pub 10/2013. PMID: 24129826.
2. Tzeng CW, Katz MH, Fleming JB, Lee JE, Pisters PW, Holmes HM, Varadhachary GR, Wolff RA, Abbruzzese JL, Vauthey JN, Aloia TA. Morbidity and Mortality after Pancreaticoduodenectomy in Patients with Borderline Resectable Type C Clinical Classification. J Gastrointest Surg 18(1):146-55; discussion 155-6, 1/2014. e-Pub 10/2013. PMID: 24129825.
3. Tzeng CW, Tran Cao HS, Lee JE, Pisters PW, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey JN, Aloia TA, Fleming JB, Katz MH. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. J Gastrointest Surg 18(1):16-24; discussion 24-5, 1/2014. e-Pub 11/2013. PMID: 24241967.
4. Bhosale P, Balachandran A, Wang H, Wei W, Hwang RF, Fleming JB, Varadhachary G, Charnsangavej C, Tamm E. CT imaging features of acinar cell carcinoma and its hepatic metastases. Abdom Imaging 38(6):1383-90, 12/2013. e-Pub 12/2012. PMID: 23232580.
5. Chatterjee D, Katz MH, Rashid A, Estrella JS, Wang H, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Abbruzzese JL, Fleming JB, Wang H. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma. Histopathology 63(6):841-51, 12/2013. e-Pub 9/2013. PMCID: PMC3836824.
6. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs 31(5):1375-83, 10/2013. e-Pub 5/2013. PMID: 23645398.
7. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol 24(9):2349-53, 9/2013. e-Pub 5/2013. PMCID: PMC3841462.
8. Varadhachary G. New Strategies for Carcinoma of Unknown Primary: The Role of Tissue-of-Origin Molecular Profiling. Clin Cancer Res 19(15):4027-4033, 8/2013. e-Pub 3/2013. PMID: 23519898.
9. Tzeng CW, Abbott DE, Cantor SB, Fleming JB, Lee JE, Pisters PW, Varadhachary GR, Abbruzzese JL, Wolff RA, Ahmad SA, Katz MH. Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis. Ann Surg Oncol 20(7):2197-203, 7/2013. e-Pub 2/2013. PMID: 23408126.
10. Overman MJ, Jiexin Zhang J, Scott Kopetz ES, Davies M, Zhi-Qin J , Stemke-Hale K, Rümmele P, Pilarsky C, Grützmann R, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary GR, Broom B, Wang H. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLOS ONE, 6/2013. PMID: 23776447.
11. Carlson H, Lenzi R, Raber MN, Varadhachary GR. A Phase II study to evaluate the efficacy and toxicity of Oxaliplatin in combination with Gemcitabine in Carcinoma of Unknown Primary. Int J Clin Oncol 18(2):226-31, 4/2013. e-Pub 1/2012. PMID: 22218909.
12. Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, Kundra V. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol 23(2):400-7, 2/2013. e-Pub 8/2012. PMID: 22932740.
13. Abbott DE, Tzeng CW, Merkow RP, Cantor SB, Chang GJ, Katz MH, Bentrem DJ, Bilimoria KY, Crane CH, Varadhachary GR, Abbruzzese JL, Wolff RA, Lee JE, Evans DB, Fleming JB. The Cost-Effectiveness of Neoadjuvant Chemoradiation is Superior to a Surgery-First Approach in the Treatment of Pancreatic Head Adenocarcinoma. Ann Surg Oncol. e-Pub 2/2013. PMID: 23397153.
14. Hornberger J, Degtiar I, Gutierrez H, Shewade A, Henner WD, Becker S, Varadhachary G, Raab S. Cost-effectiveness of gene-expression profiling for tumor-site origin. Value Health 16(1):46-56, Jan-Feb, 1/2013. PMID: 23337215.
15. Katz MH, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, Wang H, Abbruzzese J, Pisters PW, Vauthey JN, Charnsangavej C, Tamm E, Crane CH, Balachandran A. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer 118(23):5749-56, 12/2012. e-Pub 5/2012. PMID: 22605518.
16. Overman M, Wang H, Varadhachary GR. Adjuvant Chemotherapy for Resected Periampullary Adenocarcinoma. JAMA 308(18):1855-56, 11/2012. PMID: 23149995.
17. Abbott DE, Merkow RP, Cantor SB, Fleming JB, Varadhachary GR, Crane C, Bentrem DJ, Bilimoria KY. Cost-effectiveness of Treatment Strategies for Pancreatic Head Adenocarcinoma and Potential Opportunities for Improvement. Ann Surg Oncol 19(12):3659-67, 11/2012. e-Pub 9/2012. PMID: 22965567.
18. Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA, Varadhachary GR, Wang H, Katz MH. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg 16(9):1696-704, 9/2012. e-Pub 5/2012. PMID: 22644446.
19. Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB, Wang H. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118(15):3801-11, 8/2012. e-Pub 12/2011. PMCID: PMC3310937.
20. Truty MJ, Thomas RM, Katz MH, Vauthey JN, Crane C, Varadhachary GR, Wolff RA, Abbruzzese JL, Lee JE, Fleming JB. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. J Am Coll Surg 215(1):41-51; discussion 51-2, 7/2012. e-Pub 5/2012. PMID: 22608401.
21. Nystrom SJ, Hornberger JC, Varadhachary GR, Hornberger RJ, Gutierrez HR, Henner DW, Becker SH, Amin MB, Walker MG. Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival. Oncotarget 3(6):620-8, 6/2012. PMCID: PMC3442294.
22. Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 14(6):365-72, 6/2012. e-Pub 2/2012. PMCID: PMC3384860.
23. Tamm EP, Balachandran A, Bhosale PR, Katz MH, Fleming JB, Lee JH, Varadhachary GR. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am 50(3):407-28, 5/2012. e-Pub 4/2012. PMID: 22560689.
24. Kelly P, Das P, Varadhachary GR, Fontanilla HP, Krishnan S, Delclos ME, Jhingran A, Eifel PJ, Crane CH. Role of Definitive Radiation Therapy in Carcinoma of Unknown Primary in the Abdomen and Pelvis. Int J Radiat Oncol Biol Phys 82(5):2012-7, 4/2012. e-Pub 6/2011. PMID: 21640510.
25. Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, Gomez HF, Abbruzzese JL, Fleming JB, Wang H. Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol 36(3):409-17, 3/2012. e-Pub 1/2012. PMCID: PMC3288807.
26. Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, Cohen D, Wasan H. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 23(2):298-304, 2/2012. e-Pub 6/2011. PMID: 21709138.
27. Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH. Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy. Ann Surg Oncol. e-Pub 1/2012. PMID: 22258816.
28. Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, Varadhachary GR, Pisters PW, Abdalla EK, Vauthey JN, Wang H, Gomez HF, Evans DB, Abbruzzese JL, Wang H. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 118(1):268-77, 1/2012. e-Pub 7/2011. PMID: 21735446.
29. Fogelman D, Jafari M, Varadhachary GR, Xiong H, Bullock S, Ozer H, Lin E, Morris J, Cunningham P, Bennett B, Abbruzzese JL, Wolff RA. Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 68(6):1431-8, 12/2011. e-Pub 4/2011. PMID: 21479635.
30. Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, Raju RP, Fleming JB, Raju GS, Kuo YF, Lee JH. Self-Expanding Metal Stents for Biliary Drainage in Patients with Resectable Pancreatic Cancer: Single-Center Experience with 79 Cases. Dig Dis Sci 56(12):3678-84, 12/2011. e-Pub 7/2011. PMID: 21750930.
31. Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW. Survival and Quality of Life of Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Interferon-Based Chemoradiation: A Phase II Trial. Ann Surg Oncol 18(13):3615-22, 12/2011. e-Pub 6/2011. PMID: 21701927.
32. Subbiah V, Varadhachary G, Herzog CE, Huh WW. Gastric Adenocarcinoma in Children and Adolescents. Pediatric Blood Cancer 57(3):524-7, http://onlinelibrary.wiley.com/doi/10.1002/pbc.23051/abstract, 9/2011. PMCID: PMCPMC3137240.
33. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29(22):3037-43, 8/2011. e-Pub 6/2011. PMCID: PMC3157965.
34. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Bocker Edmonston T, Raber MN. Prospective Gene Signature Study Using microRNA to Identify the Tissue of Origin in Patients with Carcinoma of Unknown Primary (CUP). Clin Cancer Res 17(12):4063-70, 06/15/2011, 6/2011. PMID: 21531815.
35. Varadhachary GR, Wolff RA. The war on pancreatic cancer: are we gaining ground? Oncology (Williston Park) 24(14):1335-6, 12/2010. PMID: 21294479.
36. Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H, Crane CH, Lee JH, Tamm EP, Abbruzzese JL, Evans DB. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17(7):1794-801, 7/2010. e-Pub 2/2010. PMCID: PMC2889288.
37. Crane CH, Varadhachary GR, Wolff RA, Fleming JB. Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy. Ann Surg Oncol 17(4):950-2, 4/2010. e-Pub 12/2009. PMCID: PMC2840675.
38. Javle MM, Shroff RT, Xiong H, Varadhachary GR, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10:368, 2010. e-Pub 7/2010. PMCID: PMC2910694.
39. Varadhachary GR, Raber MN. Gene Expression Profiling in Cancers of Unknown Primary. J Clin Oncol 27(25):651, 7/2009. PMID: 19635993.
40. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma. Ann Surg Oncol 16(4), 2009 Feb 5, 2/2009. PMID: 19194760.
41. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 36(1):75-80, 2/2009. PMID: 19179191.
42. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 27(16), 1/2009. PMID: 19164203.
43. Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patient with localized pancreatic cancer. Cancer Radiother 13(2), 1/2009. PMID: 19167921.
44. Varadhachary GR, Abbruzzese JL. Novel approaches to 'borderline resectable' pancreatic tumors. Oncology 22(13):1529-30, 2008 Nov 30, 11/2008. PMID: 19227575.
45. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113(8):2046-52, 10/2008.
46. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442-8, 9/2008.
47. Wolff RA, Varadhachary GR, Evans DB. Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology, 7/2008. PMID: 18640929.
48. Varadhachary GR, Wolff Ra, Crane CH, Sun CC, Lee JE, Pister PWT, Vauthey JN, Abdalla E, Wang H, Staerkel GA, Lee JH, Ross WA, Tamm EP, Bhosale PR, Krishnan S, Das P, Ho L, Xiong H, Abbruzzese JL, Evans DB. Preoperative Gemcitabine and Cisplatin followed by Gemcitabine-based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol 26(21):3487-95, 7/2008. PMID: 18640929.
49. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PWT, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative Gemcitabine-based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head. J Clin Oncol 26(21):3496-502, 7/2008. PMID: 18640930.
50. Varadhachary GR, Raber MN, Abbruzzese JL. Colon Cancer Profile, Carcinoma of Unknown Primary. Changing paradigm and emerging definitions. Lancet Oncol 9(6):596-9, 6/2008.
51. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs 26(5):445-454, 6/2008.
52. Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206(5):833-46, 3/2008.
53. Falchook GS, Wolff RA, Varadhachary GR. Clinicopathologic features and treatment strategies for patients with pancreatic adenocarcinoma and ovarian metastases. Gynecol Oncol 108(3):515-9, 3/2008. PMID: 18164378.
54. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, Wolff RA, Crane CH, Pisters PW. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 70(3):735-43, 3/2008. PMID: 17980502.

Invited Articles

1. Varadhachary GR, Abbruzzese JL. Commentary - Borderline Resectable Pancreatic Cancer. Oncology, 12/2008.

Editorials

1. Varadhachary GR, Evans DB. Rational Study Endpoint(s) for Preoperative Trials in Pancreatic Cancer: Pathologic Response Rate, Margin Negative Resection, Overall Survival or 'All of the Above'? Ann Surg Oncol 20(12):3712-4, 11/2013. e-Pub 8/14/2013. PMID: 23943023.
2. Varadhachary GR. Molecular Profiling of CUP Cancers: Are We There Yet? Onkologie, 2/2012.

Abstracts

1. Overman MJ, Wang H, Schnabel CA, Anderson J, Erlander MG, Wolff RA, Varadhachary GR. Diagnostic utility and prognostic performance of a 92-gene cancer classifier to molecularly profile periampullary adenocarcinomas (PAA). ASCO Gastrointestinal Symposium 2013 30(J Clin Oncol), 1/2013.
2. Henner WD, Nystrom JS, Hainsworth JD, Varadhachary GR, Greco FA, Amin M, Walker M, Becker S, Pillai R, Stein S, Hornberger JC. Estimation of expected survival time using gene expression profiling for tumor site origin. 2012 ASCO Annual Meeting, 6/2012.
3. Hale KS, Wang H, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. 2012 ASCO Annual Meeting, 6/2012.
4. Varadhachary GR, Karranth S, Hainsworth JD, Wang H, Carlson HR, Lenzi R, Abbruzzese JL, Raber MN, Greco FA. Patients with carcinoma of unknown primary and “colon cancer profile”: Clinicopathologic features and survival data. 2012 ASCO Annual Meeting, 6/2012.
5. Javle MM, Shroff RT, Varadhachary GR, Wolff RA, Fogelman DR, Bhosale P, Wang X, Kar SP, Overman MJ, Sathyanarayanan S, Ayers M, Mauro DJ, Abbruzzese JL. Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC). 2012 ASCO Annual Meeting, 6/2012.
6. Shroff RT, Varadhachary GR, Crane CH, Lee JE, Lee JH, Ho L, Tamm EP, Evans DB, Abbruzzese JL, Wolff RA. Updated survival analysis of preoperative gemcitabine (gem) plus bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. 2012 ASCO Annual Meeting, 6/2012.
7. Fogelman DR, Wang XS, Hassan M, Li D, Javle MM, Katz MH, Overman MJ, Varadhachary GR, Shroff RT, Wolff RA, Abbruzzese JL. Can we identify patients with cancer at high risk for cachexia- A prospective study in pancreatic cancer (PC). ASCO Gastrointestinal Symposium 2012 30(J Clin Oncol), 1/2012.
8. Fogelman DR, Wang XS, Hassan M, Li D, Javle MM, Varadhachary GR, Shroff RT, Overman MJ, Wolff RA, Abbruzzese JL. Serum cytokines may outweigh clinical factors in predicting weight loss in advanced pancreatic cancer (PC). ASCO Gastrointestinal Symposium 2011, 1/2011.
9. Greco, FA, Lennington WJ, Spigel DR, Varadhachary GR, Hainsworth JD. Carcinoma of Unknown Primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. J Clin Oncol/Proceedings of the 2011 ASCO Annual Meeting 29, 2011.
10. Gutierrez HR, Hornberger JC, Varadhachary GR, Hornberger RJ, Henner WD, Becker S, Walker M, Amin M, Nystrom JS. Clinical utility of gene-expression profiling for tumor site origin. J Clin Oncol/Proceedings of the 2011 ASCO Annual Meeting 29, 2011.
11. Hornberger J, Amin M, Varadhachary G, Henner WD, Nystrom JS. Effect of a gene expression-based tissue of origin test’s impact on patient management for difficult-to-diagnose primary cancers. ASCO Gastrointestinal Symposium, 2011.
12. Overman MJ, Zhang J, Varadhachary GR, Hwang RF, Kapoor M, Abbruzzese JL, Wolff RA, Wang H, Broom B. Gene expression analysis of periampullary carcinomas identifies two subgroups of ampullary and duodenal carcinomas: a poor-prognosis biliary-like and a good prognosis intestinal-like. ASCO Gastrointestinal Symposium, 2011.
13. Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data. J Clin Oncol/Proceedings of the 2011 ASCO Annual Meeting 29, 2011.
14. Javle MM, Varadhachary GR, Fogelman DR, Shroff RT, Overman MJ, Ukegbu L, Bekele BN, Kar SP, Wolff RA, Abbruzzese JL. Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. J Clin Oncol/Proceedings of the 2011 ASCO Annual Meeting 29, 2011.
15. Shroff RT, Javle MM, Krishman S, Cantor SB, Lee JE, Fleming JB, Varadhachary GR, Abbruzzese JL, Wolff RA, Elting LS. Cost-effectiveness of neoadjuvant (NeoAdj) vs. adjuvant (Adj) therapies for resectable pancreatic cancer (PC). J Clin Oncol, Proceedings of the 2010 American Society of Clinical Oncology Meetings 28(7s) (#4125), 2010, 5/2010.
16. Tseng JF, Evans DB, Smith JK, Varadhachary GR, Crane CH, Wolff RA, Weinstein MC. Neoadjuvant versus upfront surgical strategies in patients with resectable pancreatic adenocarcinoma: a decision analysis. J Clin Oncol, Proceedings of the 2010 American Society of Clinical Oncology Meetings 28(7S) (#E14514), 2010, 5/2010.
17. Javle M, Varadhachary GR, Crane CH, Shroff RT, Bhosale R, Overman MJ, Weatherly J, Wolff RA, Abbruzzese JL. Phase I/II study of MD-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol; Proceedings of the 2010 American Society for Clinical Oncology Meetings 28(7s) (#4039), 2010, 5/2010.
18. Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald SR, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP). J Clin Oncol; Proceedings of the 2010 American Society of Clinical Oncology Meetings 28(7s) (#4151), 2010, 5/2010.
19. Vaccaro V, Fleming JB, Wolff RA, Evans DB, Tamm EP, Crane CH, Javle MM, Abbruzzese JL, Lee JE, Varadhachary GR. Role of surveillance CT scans in resected PC: Correlation with CA19-0 and symptoms. J Clin Oncol, Proceedings of the 2010 American Society of Clinical Oncology Meetings 28(7s) (#4113), 2010, 5/2010.
20. Javle M, Varadhachary G, Bhosale P, Schroff R, Ukegbu L, Overman M, Wolff R, Abbruzzese J. Phase I Study of MK-0646, The Humanized Monoclonal Antibody Against IGF-1R in Combination with Gemcitabine or Gemcitabine + Erlotinib (E) for Advanced Previously Untreated Pancreatic Cancer, 9/2009.
21. Varadhachary GR, McConkey D, Woonyoung C, Marquis L, Carlson H, Bullock S, Abbruzzese JL. A Phase II Study of Bortezomib in Combination with Carboplatin in Patients with Metastatic Pancreatic Cancer. 11th World Congress on Gastrointestinal Cancer, 6/2009.
22. Parker PA, Baile W, Cohen I, Abbruzzese J, Varadhachary G, Ho L, LaPushin T, Dayao P, Lenzi R. Illness uncertainty, sense of coherence, and psychosocial adjustment in patients with pancreatic cancer. Annals of Behavioral Medicine 37(51), 4/2009.
23. Fogelman DR, Varadhachary G,Xiong HQ, Chang DZ, Bullock SA, Ozer H, Wolff RA, Abbruzzese JL. Final results of a bi-institution phase II study of gemcitabine, oxaliplatin, and bevacizumab for advanced pancreatic cancer. Proc Am Soc Clin Onc 2009 GI ASCO Symposium (#182), January 2009, 1/2009.
24. Shroff RT, Krishnan S, Javle M, Varadhachary GR,Crane CH, Wen S, Abbruzzese JL, Wolff RA, Overman MJ. Improved relapse-free survival with the addition of systemic chemotherapy to adjuvant chemoradiationt for high-risk ampullary adenocarcinoma. Proc Am Soc Clin Oncol 2009 GI ASCO Symposium (#250), 1/2009.
25. Shroff RT, Xiong HQ, Varadhachary GR, Kaseb A, Fogelman DR, Ukegbu LT, Blais JC, Wolff RA, Abbruzzese JL, Javle M. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies. Proc Am Soc Clin Oncol 2009 GI ASCO Symposium (#246), January 2009, 1/2009.
26. Hammad N, Phillip PA, Shields AF, Sarkar FH, Abbruzzese JL, Kaseb AO, Javle MM, Varadhachary GR,Wolff RA, El-Rayes BF. A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer. Proc Am Soc Clin Oncol (#15540), May 20, 5/2008.
27. Overman MJ, Varadhachary GR,Lin E, Morris J, Adinin R, Abbruzzese JL, Wolff RA. Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater. Proc Am Soc Clin Oncol 2008 Annual Meeting (#4538), May 20, 5/2008.
28. Katz MH, Fleming JB, Sun CC, Wolff RA, Crane CH, Evans DB, Varadhachary GR. Preoperative CA 19-9 in the Neoadjuvant Treatment of Resectable Pancreatic Cancer. Pancreas Club, 5/2008.
29. Varadhachary GR,Wolff RA, Crane CH, Lee JE, Abdalla EK, Lee JH, Pisters PW, Ho L, Abbruzzese JL, Evans DB. Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2008 Annual Meeting (#4630), May 20, 5/2008.
30. Hammad N, Philip PA, Shields AF, Abbruzzese JL, Kaseb AO, Javle MM, Varadhachary GR,Wolff RA, Sarkar FH, El-Rayes BF. A phase II study of isoflavone (Novasoy), gemcitabine, and erlotinib in locally advanced or metastatic pancreatic cancer. Gastrointestinal Cancers Symposium, 1/2008.
31. Javle MM, Okazaki T, Wolff RA, Varadhachary GR, Ho L, Crane CH, San Miguel A, Evans DB, Abbruzzese JL, Li D. Combined effect of single nucleotide polymorphisms of gemcitabine metabolic genes on pancreatic cancer survival and drug toxicity. ASCO Gastrointestinal Cancers Symposium, 1/2008.
32. Settle SH, Crane CH, Das P, Varadhachary GR, Tamm EP, Javle M, Hodges JC, Krishnan S, Evans DB, Wolff RA. Novel use of focal high-dose IMRT for borderline resectaable pancreatic cancer. ASCO Gastrointestinal Cancers Symposium, 1/2008.
33. Varadhachary GR,Wolff RA, Crane CH, Lee JE, Abdalla EK, Lee JH, Pisters PW, Ho L, Abbruzzese JL, Evans DB. Preoperative gemcitabine plus bevacizumab-based chemoradiation for resectable pancreatic adenocarcinoma. ASCO Gastrointestinal Cancers Symposium, 1/2008.

Book Chapters

1. Halperin DM, Varadhachary GR. Resectable, borderline resectable and locally advanced pancreatic cancer: What does it matter? In: Curr Oncol Rep. 16, 2. Springer: Philadelphia, PA, 366, 2014. ISBN: 24445498.
2. Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of Unknown Primary. In: Abeloff's Clinical Oncology. Chapter 94, Fifth. Ed(s) Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Elsevier: Philadelphia, PA, 1792-1803, 2013.
3. Matamoras A, Varadhachary G. Cancer of Unknown Primary. In: Oncologic Imaging: A Multidisciplinary Approach. Chapter 35. Ed(s) Silverman P. Elsevier: Philadelphia, 611-20, 2012.
4. Tamm EP, Varadhachary GR, Fleming JB. Pancreatic Ductal Adenocarcinoma. In: Oncologic Imaging: A Multidisciplinary Approach. Chapter 11. Ed(s) Silverman P. Elsevier: Philadelphia, 153-172, 2012. ISBN: 978-1-4377-2232-1.
5. Varadhachary GR, Abbruzzese JL. Carcinoma of Unknown Primary. In: Harrison's Principles of Internal Medicine, 18th, 2011.
6. Glover KY, Varadhachary GR,Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of Unknown Primary. In: Clinical Oncology, Fourth Edition. Churchill Livingstone, 2057-2074, 2008. ISBN: 978--0-443-06694-8.
7. Varadhachary GR,Abbruzzese JL. Carcinoma of Unknown Primary. In: Harrison's Principles of Internal Medicine, 2008.
8. Raut CP, Varadhachary G,Wang H, Tamm E, Fleming JB, Evans DB. Margin Status following Pancreaticoduodenectomy for Pancreatic Cancer. In: Diseases of the Pancreas-Current Surgical Therapy. Chapter 54, Beger Matsuno and Cameron. Springer, 611-623, 2008.
9. Varadhachary GR,Abbruzzese J. Resected Pancreatic Cancer. In: Diseases of the Pancreas-Current Surgical Therapy. Chapter 59, Beger Matsuno and Cameron. Springer, 675-687, 2008.

Letters to the Editor

1. Hainsworth JD, Greco AF, Talantov D, Varadhachary GR. Reply to “Morphologic and More Specific Immunohistochemical Stains are Fundamental Prerequisites in Detection of Unknown Primary Cancer” by Giulio Rossi et al. Journal of Clinical Oncology:651-652, 2/2009.

Manuals, Teaching Aids, Other Teaching Publications

1. Varadhachary, GR. ASCO University Tumor Board: Cancer Unknown Primary: web-based, 4/2010.
2. Varadhachary GR. When the Diagnosis is Cancer of Unknown Primary: Guidelines for Care. CancerCare Telephone Workshop: New York, 6/2009.
3. Varadhachary GR, Crane CH, Evans DB, Tamm E. Virtual Pancreatic Tumor Board. Interactive Web based education. Postgraduate Institute for Medicine and IMPACt, Inc. Houston, Texas, 9/2008.
4. OncoLog. 53, 3. Scientific Publications: Houston, Texas, 1-5, 3/2008.

Grant & Contract Support

Title: A Novel Preoperative Platform in Pancreatic Cancer for Mechanistic Studies
Funding Source: Lustgarten Foundation for Pancreatic Cancer Research
Role: Principal Investigator
Duration: 5/1/2011 - 10/31/2014
 
Title: Proteasome Inhibition and ER Stress
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: David McConkey
Duration: 1/1/2009 - 11/30/2013
 
Title: Prospective Gene Signature Study using microRNA to Predict the Tissue of Origin in Patients with Cancer of Unknown Primary Site (CUP)
Funding Source: Rosetta Genomics
Role: Co-Investigator
Principal Investigator: James Abbruzzese
Duration: 4/1/2008 - 4/30/2013
 
Title: Overexpression and Prevalence of Molecular Markers in Patients with Cancer of the Unknown Primary
Funding Source: Institutional Research Grant
Role: Principal Investigator
Duration: 1/2005 - 8/31/2005

Last updated: 5/29/2014